No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1995 and headquartered in North Point, Hong Kong, China Medical System Holdings Limited functions as an investment holding company with a primary focus on the development, marketing, and distribution of a wide array of pharmaceutical products throughout the People's Republic of China. The company's extensive portfolio addresses numerous therapeutic areas. Its cardiovascular offerings include Plendil for hypertension and stable angina, XinHuoSu for acute heart failure, and Imdur for coronary heart disease, chronic heart failure, and myocardial infarction prevention. For mental health and neurological support, it provides Deanxit to treat mild-to-moderate depression and anxiety, along with Parlodel tablets for endocrine and neuro system indications. Digestive and liver conditions are managed with products such as Ursofalk for gallstones and cholestatic liver disease, Salofalk for ulcerative colitis and Crohn's disease, Bioflor for diarrhea, Combizym for dyspepsia, and Ganfule capsules for primary liver cancer, plus MOVICOL for chronic constipation. The company also markets Augentropfen Stulln Mono eye drops for senile macula degeneration and asthenopia, Hirudoid for blunt trauma and superficial phlebitis, Elcatonin injection for osteoporosis, and Lamisil tablets for fungal infections. Respiratory issues are addressed by YiNuoShu, while infectious diseases benefit from DanShenTong capsules (for various infections like acne, tonsillitis, and boils) and YinlianQinggan granules for hepatitis. XiDaKang, a protein hydrolysate oral solution, is also part of its offerings. Beyond its pharmaceutical endeavors, the group is also actively involved in agriculture and livestock operations. China Medical System Holdings Limited operates as a subsidiary of Treasure Sea Limited.
web.cms.net.cn/zh/homeNo one on the platform currently holds 0867.HK.
No tracked institution reports a position in 0867.HK as of their last filing.
No one on the platform has traded 0867.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.1% | 17.2% | 20.6% | — | — | — |
| Rev. Growth % | 9.9% | 3.4% | ||||
| Profit Margin % | 18.1% | 28.3% | 30.4% | |||
| Free Cash Flow Margin % | 3.0% | 20.4% | 24.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.1B | +23.5% | $0.86 | $0.81–$0.90 | — | 1 |
| 2027 | $12.0B | +18.2% | $1.00 | $0.96–$1.04 | — | 3 |
| 2028 | $14.3B | +19.7% | $1.19 | $1.12–$1.25 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-17 | $0.46 | $0.47 | +1.9% |
| 2026-03-16 | $0.32 | $0.26 | -20.7% |
| 2025-08-18 | $0.41 | $0.43 | +5.0% |
| 2024-12-31 | $0.36 | $0.31 | -14.1% |
| 2024-06-30 | $0.34 | $0.40 | +16.6% |
| 2023-12-31 | $0.59 | $0.22 | -63.5% |
| 2023-06-30 | $0.78 | $0.85 | +8.9% |
| 2022-12-31 | $0.71 | $0.68 | -4.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 0867.HKChina Medical System Holdings Limited | $10.90 | -2.07% | $26.5B | — |
| 0013.HKHUTCHMED (China) Limited | $21.58 | +0.84% | $18.8B | — |
| 0512.HKGrand Pharmaceutical Group Limited | $4.91 | +0.51% | $17.2B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.20 | -0.68% | $32.8B | — |
| 1513.HKLivzon Pharmaceutical Group Inc. |
| $20.80 |
| -1.33% |
| $22.7B |
| — |
| 2096.HKSimcere Pharmaceutical Group Limited | $11.25 | -1.23% | $28.9B | — |
| 2575.HKXuanzhubio-b | $8.30 | -2.12% | $4.3B | — |
Source: Financial Modeling Prep · peers by sector/industry